Pharma-Bio Serv Current Assets
The Current Assets of Pharma-Bio Serv (PBSV) as of Nov 3, 2026 is 2.53 M USD. In the previous year, Current Assets was 2.95 M USD — a change of -14.26% (lower).
Get this data via API
Financial Data API
Current Assets
2.53 MUSD
YoY
-14.26%
Last updated:
The Pharma-Bio Serv Current Assets history
3 Years
10 Years
25 Years
Max
| YEAR | Current Assets | YoY |
|---|---|---|
| 2.53 MUSD | -14.26% | |
| 2.95 MUSD | -33.24% | |
| 4.42 MUSD | -19.28% | |
| 5.48 MUSD | +18.81% | |
| 4.61 MUSD | -83.86% | |
| 28.58 MUSD | +10.05% | |
| 25.97 MUSD | +10.95% | |
| 23.41 MUSD | +7.21% | |
| 21.84 MUSD | +0.96% | |
| 21.63 MUSD | -7.04% | |
| 23.27 MUSD | +4.20% | |
| 22.33 MUSD | +10.08% | |
| 20.28 MUSD | +154.74% | |
| 7.96 MUSD | +53.40% | |
| 5.19 MUSD | +85.99% | |
| 2.79 MUSD | +19.32% | |
| 2.34 MUSD | -32.08% | |
| 3.44 MUSD | -10.24% | |
| 3.84 MUSD | -55.12% | |
| 8.55 MUSD | +17,000.00% | |
| 50,000.00USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Pharma-Bio Serv Stock analysis
Frequently Asked Questions about Pharma-Bio Serv stock
Current Assets of Pharma-Bio Serv is 2.53 M USD in 2025.
Current Assets of Pharma-Bio Serv changed from 2.95 M USD to 2.53 M USD, representing a -14.26% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Current Assets Pharma-Bio Serv since 2006 – with annual values, charts, and detailed analysis.
Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.
Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Pharma-Bio Serv historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Balance Sheet — Pharma-Bio Serv
All Key Metrics — Pharma-Bio Serv
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth